{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T09:01:20Z","timestamp":1648803680009},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T00:00:00Z","timestamp":1385078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00108-013-3319-3","type":"journal-article","created":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T02:26:48Z","timestamp":1384914408000},"page":"1427-1433","source":"Crossref","is-referenced-by-count":0,"title":["Was ist gesichert in der Therapie der chronischen Virushepatitis?"],"prefix":"10.1007","volume":"54","author":[{"given":"C.","family":"H\u00f6ner zu Siederdissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,22]]},"reference":[{"key":"3319_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2188\/jea.JE20100010","volume":"20","author":"Robert","year":"2010","unstructured":"Robert Koch-Institut (2010) Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis\u00a0B, C und\u00a0D im Jahr 2009. Epidemiol Bull 20:177\u2013190","journal-title":"Epidemiol Bull"},{"key":"3319_CR2","doi-asserted-by":"crossref","unstructured":"Cornberg M, Protzer U, Petersen J et\u00a0al (2011) Prophylaxis, diagnosis and therapy of hepatitis\u00a0B virus infection \u2013 the German guideline. Z\u00a0Gastroenterol 49:871\u2013930","DOI":"10.1055\/s-0031-1273462"},{"key":"3319_CR3","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis\u00a0B virus infection. J\u00a0Hepatol 57:167\u2013185","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"3319_CR4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","volume":"58","author":"Lee","year":"2013","unstructured":"Lee MH, Yang HI, Liu J et\u00a0al (2013) Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis\u00a0B patients: risk scores integrating host and virus profiles. Hepatology 58:546\u2013554","journal-title":"Hepatology"},{"key":"3319_CR5","first-page":"451","volume":"56","author":"Cornberg","year":"2010","unstructured":"Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer\u00a0H (2010) Treatment of chronic hepatitis\u00a0B. Minerva Gastroenterol Dietol 56:451\u2013465","journal-title":"Minerva Gastroenterol Dietol"},{"key":"3319_CR6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","volume":"54","author":"Liaw","year":"2011","unstructured":"Liaw YF, Jia JD, Chan HL et\u00a0al (2011) Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis\u00a0B\u00a0e antigen seroconversion rates in hepatitis\u00a0B virus genotypes\u00a0B or C. Hepatology 54:1591\u20131599","journal-title":"Hepatology"},{"key":"3319_CR7","doi-asserted-by":"crossref","unstructured":"Chan HL, Thompson A, Martinot-Peignoux M et\u00a0al (2011) Hepatitis\u00a0B surface antigen quantification: why and how to use it in 2011 \u2013 a core group report. J\u00a0Hepatol 55:1121\u20131131","DOI":"10.1016\/j.jhep.2011.06.006"},{"key":"3319_CR8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","volume":"61","author":"Janssen","year":"2012","unstructured":"Janssen HLA, Sonneveld MJ, Brunetto MR (2012) Quantification of serum hepatitis\u00a0B surface antigen: is it useful for the management of chronic hepatitis\u00a0B? Gut 61:641\u2013645","journal-title":"Gut"},{"key":"3319_CR9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M et\u00a0al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis\u00a0B: a 5-year open-label follow-up study. Lancet 381:468\u2013475","journal-title":"Lancet"},{"key":"3319_CR10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS et\u00a0al (2010) Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis\u00a0B. Hepatology 52:886\u2013893","journal-title":"Hepatology"},{"key":"3319_CR11","doi-asserted-by":"crossref","unstructured":"Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok\u00a0A (2010) Incidence of hepatocellular carcinoma in chronic hepatitis\u00a0B patients receiving nucleos(t)ide therapy: a systematic review. J\u00a0Hepatol 53:348\u2013356","DOI":"10.1016\/j.jhep.2010.02.035"},{"key":"3319_CR12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M et\u00a0al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis\u00a0B virus infection. Hepatology 58:98\u2013107","journal-title":"Hepatology"},{"key":"3319_CR13","unstructured":"Chevaliez S, H\u00e9zode C, Bahrami S et\u00a0al (2012) Long-term hepatitis\u00a0B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely. J\u00a0Hepatol 58:683\u2013676"},{"key":"3319_CR14","doi-asserted-by":"crossref","unstructured":"Zoutendijk R, Hansen BE, Vuuren AJ van et\u00a0al (2011) Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis\u00a0B and prediction of HBsAg loss. J\u00a0Infect Dis 204:415\u2013418","DOI":"10.1093\/infdis\/jir282"},{"key":"3319_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","volume":"7","author":"Wedemeyer","year":"2010","unstructured":"Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis\u00a0D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31\u201340","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3319_CR16","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Yurdayd\u00ecn C, Dalekos GN et\u00a0al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N\u00a0Engl J Med 364:322\u2013331","DOI":"10.1056\/NEJMoa0912696"},{"key":"3319_CR17","unstructured":"Heidrich B, Yurdaydin C, Kabacam G et\u00a0al (2013) Long-term follow-up after PEG-IFN2a-based therapy of chronic hepatitis delta. J\u00a0Hepatol 58: Abstract\u00a046, S20"},{"key":"3319_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11908-012-0307-z","volume":"15","author":"Heidrich","year":"2013","unstructured":"Heidrich B, Manns MP, Wedemeyer H (2013) Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep 15:31\u201338","journal-title":"Curr Infect Dis Rep"},{"key":"3319_CR19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bpg.2012.09.009","volume":"26","author":"Maasoumy","year":"2012","unstructured":"Maasoumy B, Wedemeyer H (2012) Natural history of acute and chronic hepatitis\u00a0C. Best Pract Res Clin Gastroenterol 26:401\u2013412","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3319_CR20","doi-asserted-by":"crossref","unstructured":"Manns MP, Pockros PJ, Norkrans G et\u00a0al (2013) Long-term clearance of hepatitis\u00a0C virus following interferon \u03b1-2b or peginterferon \u03b1-2b, alone or in combination with ribavirin. J\u00a0Viral Hepat 20:524\u2013529","DOI":"10.1111\/jvh.12074"},{"key":"3319_CR21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","volume":"139","author":"Swain","year":"2010","unstructured":"Swain MG, Lai MY, Shiffman ML et\u00a0al (2010) A sustained virologic response is durable in patients with chronic hepatitis\u00a0C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139:1593\u20131601","journal-title":"Gastroenterology"},{"key":"3319_CR22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","volume":"144","author":"Chen","year":"2013","unstructured":"Chen J, Florian J, Carter W et\u00a0al (2013) Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis\u00a0C therapies. Gastroenterology 144:1450\u20131455.e2","journal-title":"Gastroenterology"},{"key":"3319_CR23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/apt.12350","volume":"38","author":"Rutter","year":"2013","unstructured":"Rutter K, Hofer H, Beinhardt S et\u00a0al (2013) Durability of SVR in chronic hepatitis\u00a0C patients treated with peginterferon-\u03b12a\/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 38:118\u2013123","journal-title":"Aliment Pharmacol Ther"},{"key":"3319_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"Backus","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR et\u00a0al (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis\u00a0C. Clin Gastroenterol Hepatol 9:509\u2013516.e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3319_CR25","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"Van","year":"2012","unstructured":"Van der Meer AJ, Veldt BJ, Feld JJ et\u00a0al (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis\u00a0C and advanced hepatic fibrosis. JAMA 308:2584\u20132593","journal-title":"JAMA"},{"key":"3319_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","volume":"31","author":"Cornberg","year":"2011","unstructured":"Cornberg M, Razavi HA, Alberti A et\u00a0al (2011) A systematic review of hepatitis\u00a0C virus epidemiology in Europe, Canada and Israel. Liver Int 31(Suppl\u00a02):30\u201360","journal-title":"Liver Int"},{"key":"3319_CR27","unstructured":"Sarrazin C, Berg T, Cornberg M et\u00a0al (2012) Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis\u00a0C. Z\u00a0Gastroenterol 50:57\u201372"},{"key":"3319_CR28","doi-asserted-by":"crossref","first-page":"e55285","DOI":"10.1371\/journal.pone.0055285","volume":"8","author":"Maasoumy","year":"2013","unstructured":"Maasoumy B, Port K, Markova AA et\u00a0al (2013) Eligibility and safety of triple therapy for hepatitis\u00a0C: lessons learned from the first experience in a real world setting. PLoS One 8:e55285","journal-title":"PLoS One"},{"key":"3319_CR29","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/gutjnl-2012-302910","volume":"61","author":"Dusheiko","year":"2012","unstructured":"Dusheiko G, Wedemeyer H (2012) New protease inhibitors and direct-acting antivirals for hepatitis\u00a0C: interferon\u2019s long goodbye. Gut 61:1647\u20131652","journal-title":"Gut"},{"key":"3319_CR30","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","volume":"381","author":"Kowdley","year":"2013","unstructured":"Kowdley KV, Lawitz E, Crespo I et\u00a0al (2013) Sofosbuvir with pegylated interferon\u00a0alfa-2a and ribavirin for treatment-naive patients with hepatitis\u00a0C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase\u00a02 trial. Lancet 381:2100\u20132107","journal-title":"Lancet"},{"key":"3319_CR31","first-page":"2","volume":"32","author":"European","year":"2012","unstructured":"European Association For The Study Of The Liver (2012) 2011 European Association of the Study of the Liver hepatitis\u00a0C virus clinical practice guidelines. Liver Int 32(Suppl\u00a01):2\u20138","journal-title":"Liver Int"},{"key":"3319_CR32","doi-asserted-by":"crossref","unstructured":"Sarrazin C, Berg T, Ross RS et\u00a0al (2010) Prophylaxis, diagnosis and therapy of hepatitis\u00a0C virus (HCV) infection: the German guidelines on the management of HCV infection. Z\u00a0Gastroenterol 48:289\u2013351","DOI":"10.1055\/s-0028-1110008"},{"key":"3319_CR33","doi-asserted-by":"crossref","unstructured":"Lawitz E, Mangia A, Wyles D et\u00a0al (2013) Sofosbuvir for previously untreated chronic hepatitis\u00a0C infection. N\u00a0Engl J Med 368:1878\u20131887","DOI":"10.1056\/NEJMoa1214853"},{"key":"3319_CR34","doi-asserted-by":"crossref","unstructured":"Jacobson IM, Gordon SC, Kowdley KV et\u00a0al (2013) Sofosbuvir for hepatitis\u00a0C genotype\u00a02 or 3 in patients without treatment options. N\u00a0Engl J Med 368:1867\u20131877","DOI":"10.1056\/NEJMoa1214854"},{"key":"3319_CR35","doi-asserted-by":"crossref","unstructured":"Pischke S, Wedemeyer H (2013) Hepatitis\u00a0E virus infection: multiple faces of an underestimated problem. J\u00a0Hepatol 58:1045\u20131046","DOI":"10.1016\/j.jhep.2012.12.013"},{"key":"3319_CR36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1053\/j.gastro.2012.02.014","volume":"142","author":"Wedemeyer","year":"2012","unstructured":"Wedemeyer H, Pischke S, Manns MP (2012) Pathogenesis and treatment of hepatitis\u00a0E virus infection. Gastroenterology 142:1388\u20131397.e1","journal-title":"Gastroenterology"},{"key":"3319_CR37","doi-asserted-by":"crossref","unstructured":"Wenzel JJ, Preiss J, Schemmerer M et\u00a0al (2013) Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis\u00a0E seroprevalence estimates. J\u00a0Infect Dis 207:497\u2013500","DOI":"10.1093\/infdis\/jis688"},{"key":"3319_CR38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/lt.21958","volume":"16","author":"Pischke","year":"2010","unstructured":"Pischke S, Suneetha PV, Baechlein C et\u00a0al (2010) Hepatitis\u00a0E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 16:74\u201382","journal-title":"Liver Transpl"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-013-3319-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3319-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T13:16:57Z","timestamp":1564838217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-013-3319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,22]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3319"],"URL":"https:\/\/doi.org\/10.1007\/s00108-013-3319-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,22]]}}}